- Home
- SNAX vs AZTR Comparison
SNAX vs AZTR Comparison
Compare SNAX & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAX
- AZTR
- Stock Information
- Founded
- SNAX 2017
- AZTR 2014
- Country
- SNAX United States
- AZTR United States
- Employees
- SNAX N/A
- AZTR N/A
- Industry
- SNAX Packaged Foods
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- SNAX Consumer Staples
- AZTR Health Care
- Exchange
- SNAX Nasdaq
- AZTR Nasdaq
- Market Cap
- SNAX 3.1M
- AZTR 3.6M
- IPO Year
- SNAX N/A
- AZTR 2023
- Fundamental
- Price
- SNAX $0.63
- AZTR $0.41
- Analyst Decision
- SNAX
- AZTR
- Analyst Count
- SNAX 0
- AZTR 0
- Target Price
- SNAX N/A
- AZTR N/A
- AVG Volume (30 Days)
- SNAX 54.9K
- AZTR 121.9K
- Earning Date
- SNAX 11-13-2024
- AZTR 11-12-2024
- Dividend Yield
- SNAX N/A
- AZTR N/A
- EPS Growth
- SNAX N/A
- AZTR N/A
- EPS
- SNAX N/A
- AZTR N/A
- Revenue
- SNAX $19,364,939.00
- AZTR $97,500.00
- Revenue This Year
- SNAX $30.31
- AZTR $494.75
- Revenue Next Year
- SNAX N/A
- AZTR N/A
- P/E Ratio
- SNAX N/A
- AZTR N/A
- Revenue Growth
- SNAX N/A
- AZTR N/A
- 52 Week Low
- SNAX $0.55
- AZTR $0.40
- 52 Week High
- SNAX $2.95
- AZTR $68.40
- Technical
- Relative Strength Index (RSI)
- SNAX 26.04
- AZTR 37.74
- Support Level
- SNAX $0.55
- AZTR $0.40
- Resistance Level
- SNAX $0.94
- AZTR $0.51
- Average True Range (ATR)
- SNAX 0.07
- AZTR 0.03
- MACD
- SNAX -0.02
- AZTR -0.00
- Stochastic Oscillator
- SNAX 22.88
- AZTR 29.84
About SNAX Stryve Foods Inc.
Stryve Foods Inc is a healthy snacking company that manufactures, markets, and sells differentiated healthy snacking products. The company offers convenient snacks that are lower in sugar and carbohydrates and higher in protein than other snacks.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.